Arsenic in Chicken Leads to Stopped Drug Sales: FDA
Get the world’s most fascinating discoveries delivered straight to your inbox.
You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
Delivered Daily
Daily Newsletter
Sign up for the latest discoveries, groundbreaking research and fascinating breakthroughs that impact you and the wider world direct to your inbox.
Once a week
Life's Little Mysteries
Feed your curiosity with an exclusive mystery every week, solved with science and delivered direct to your inbox before it's seen anywhere else.
Once a week
How It Works
Sign up to our free science & technology newsletter for your weekly fix of fascinating articles, quick quizzes, amazing images, and more
Delivered daily
Space.com Newsletter
Breaking space news, the latest updates on rocket launches, skywatching events and more!
Once a month
Watch This Space
Sign up to our monthly entertainment newsletter to keep up with all our coverage of the latest sci-fi and space movies, tv shows, games and books.
Once a week
Night Sky This Week
Discover this week's must-see night sky events, moon phases, and stunning astrophotos. Sign up for our skywatching newsletter and explore the universe with us!
Join the club
Get full access to premium articles, exclusive features and a growing list of member rewards.
The company that manufactures an animal drug that has been used since the 1940s to fatten up chickens is voluntarily halting sales of the drug, following a Food and Drug Administration (FDA) report.
Alpharma, a subsidiary of Pfizer Inc., will voluntarily suspend U.S. sales of the animal drug 3-Nitro (Roxarsone) after the report showed that the livers of chickens treated with the drug contained low levels of inorganic arsenic, a known carcinogen.
The drug is used to control intestinal parasites and improve weight gain in poultry, said Bernadette Dunham, director of FDA's Center for Veterinary Medicine, at a news conference today (June 8).
While the levels of arsenic detected were very low and do not pose a health risk, sales are being halted because the tests had raised concerns of a "completely avoidable exposure to a carcinogen," said Michael R. Taylor, FDA deputy commissioner for foods.
The drug is fairly broadly used by the poultry industry, said Dr. David Goldman, of the U.S. Public Health Service Commissioned Corps. The drug is also approved for use in swine and turkeys.
The FDA study was prompted by scientific reports showing that organic arsenic, which is the form of arsenic in 3-Nitro, could be converted to the more toxic inorganic arsenic from in the environment, the administration said. The study was conducted to find whether this conversion could happen in animals as well.
Sales of 3-Nitro will continue for 30 days from today, according to Alpharma's plan. Allowing sales for this period will provide time for animal producers to transition to other treatment strategies and will help ensure that animal health and welfare needs are met, the company said.
Get the world’s most fascinating discoveries delivered straight to your inbox.
Pass it on: Alpharma, the company that manufactures an animal drug used to fatten up chickens, is voluntarily halting sales of the drug, following a FDA report.
This story was provided by MyHealthNewsDaily, sister site to LiveScience. Follow MyHealthNewsDaily Twitter @MyHealth_MHND.

